Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00689728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00689728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
May 31, 2010
Enrollment
100 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid